1. Home
  2. AUST vs LNAI Comparison

AUST vs LNAI Comparison

Compare AUST & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Austin Gold Corp.

AUST

Austin Gold Corp.

HOLD

Current Price

$1.67

Market Cap

26.0M

Sector

N/A

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.93

Market Cap

23.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AUST
LNAI
Founded
2020
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.0M
23.2M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
AUST
LNAI
Price
$1.67
$0.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
121.4K
268.9K
Earning Date
02-26-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$0.81
52 Week High
$2.94
$14.00

Technical Indicators

Market Signals
Indicator
AUST
LNAI
Relative Strength Index (RSI) 48.07 N/A
Support Level $1.46 N/A
Resistance Level $1.70 N/A
Average True Range (ATR) 0.16 0.00
MACD -0.02 0.00
Stochastic Oscillator 40.38 0.00

Price Performance

Historical Comparison
AUST
LNAI

About AUST Austin Gold Corp.

Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: